• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Sight Sciences Inc.

    11/12/25 8:11:08 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001565950
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Sight Sciences, Inc.
    SEC File Number
    001-40587
    Address of Issuer
    4040 CAMPBELL AVE,
    SUITE 100
    MENLO PARK
    CALIFORNIA
    94025
    Phone
    (415) 889-0550
    Name of Person for Whose Account the Securities are To Be Sold
    Link Matthew
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Former Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    50000347995.005287173111/11/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common11/11/2025Options Granted - 11/14/2023IssuerCheckbox not checked5000011/11/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Matthew Link
    4040 Campbell Ave
    Suite 100
    Menlo Park � CA � 94025
    Common09/12/20251000035227.21
    Matthew Link
    4040 Campbell Ave
    Suite 100
    Menlo Park � CA � 94025
    Common09/16/20251599055291.81
    Matthew Link
    4040 Campbell Ave
    Suite 100
    Menlo Park � CA � 94025
    Common09/19/20252000073400.00
    Matthew Link
    4040 Campbell Ave
    Suite 100
    Menlo Park � CA � 94025
    Common09/23/20252075373350.73
    Matthew Link
    4040 Campbell Ave
    Suite 100
    Menlo Park � CA � 94025
    Common10/03/20251500049276.20
    Matthew Link
    4040 Campbell Ave
    Suite 100
    Menlo Park � CA � 94025
    Common10/17/20251052947015.14
    Matthew Link
    4040 Campbell Ave
    Suite 100
    Menlo Park � CA � 94025
    Common10/22/2025886744511.45

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/12/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Matthew Link

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SGHT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    8/8/2025$5.00Hold → Buy
    Lake Street
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    8/24/2023$12.00 → $8.40Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Encrantz Staffan bought $381,958 worth of shares (90,525 units at $4.22) and was granted 30,952 shares, increasing direct ownership by 10% to 1,377,964 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    6/6/25 9:10:58 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Director Encrantz Staffan bought $376,429 worth of shares (98,782 units at $3.81), increasing direct ownership by 9% to 1,256,487 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    6/3/25 9:57:16 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    5/29/25 9:31:17 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Hayden Jeremy B. exercised 44,850 shares at a strike of $1.96 and sold $362,388 worth of shares (44,850 units at $8.08) (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    11/26/25 6:52:36 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    EVP, Operations & R&D Taylor Brenton sold $101,791 worth of shares (14,418 units at $7.06), decreasing direct ownership by 8% to 170,831 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    11/18/25 5:24:22 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Chief Legal Officer Hayden Jeremy B. exercised 3,150 shares at a strike of $1.96 and sold $25,232 worth of shares (3,150 units at $8.01) (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    11/14/25 7:48:07 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans

    MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, announced today the results from three key published manuscripts that further demonstrate the value of an interventional mindset in treating glaucoma. "We are proud to continuously support the study of interventional glaucoma treatment, especially in highlighting critical groups of patients that may benefit from active surgical interventions. These results demonstrate that when surgeons are given the right solut

    11/11/25 7:00:00 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated third quarter 2025 total revenue of $19.9 million, a decrease of 1% compared to the same period in the prior year. The Company's Surgical Glaucoma revenue increased

    11/6/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sight Sciences upgraded by Lake Street with a new price target

    Lake Street upgraded Sight Sciences from Hold to Buy and set a new price target of $5.00

    8/8/25 8:25:35 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on Sight Sciences with a new price target

    UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50

    12/6/24 8:14:13 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences downgraded by Lake Street with a new price target

    Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously

    11/4/24 8:26:06 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    SEC Filings

    View All

    SEC Form 144 filed by Sight Sciences Inc.

    144 - Sight Sciences, Inc. (0001531177) (Subject)

    11/12/25 8:11:08 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Sight Sciences Inc.

    10-Q - Sight Sciences, Inc. (0001531177) (Filer)

    11/6/25 4:19:44 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    11/6/25 4:11:19 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Financials

    Live finance-specific insights

    View All

    Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated third quarter 2025 total revenue of $19.9 million, a decrease of 1% compared to the same period in the prior year. The Company's Surgical Glaucoma revenue increased

    11/6/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

    MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 6, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the even

    10/23/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated second quarter 2025 total revenue of $19.6 million, a decrease of 8% compared to the same period in the prior year. This expected decline was primarily due to low

    8/7/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    11/14/24 11:57:36 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    2/14/24 5:24:02 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sight Sciences Inc.

    SC 13G - Sight Sciences, Inc. (0001531177) (Subject)

    2/13/24 6:52:37 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $SGHT
    Leadership Updates

    Live Leadership Updates

    View All

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Sight Sciences Appoints Gary Burbach to its Board of Directors

    MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

    4/22/25 4:05:00 PM ET
    $BWXT
    $SGHT
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

    MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

    11/7/24 4:04:00 PM ET
    $INGN
    $SGHT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments